Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2022-01-20 00:00:00 ET · period of report 2022-01-18 · accession 0001725160-22-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-01-20 | 2022-01-18+ | ZNTL | Voliotis Dimitris | SVP, Clinical Development | S - Sale+OE | $61.36 | -30.0K | 7,550 | -80% | -$1.84M |
| DM | 2022-01-20 | 2022-01-18+ | ZNTL | Voliotis Dimitris | SVP, Clinical Development | M - OptEx | $18.00 | +30.0K | 16.2K | New | +$540.0K |
| DM | 2022-01-20 | 2022-01-18+ | ZNTL | Voliotis Dimitris | SVP, Clinical Development | M - OptEx | $0.00 | -30.0K | 134.9K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-20 | S | D | 1,657 | $61.21 | 6,250 | D | — | — | (F10) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.01 to $61.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2022-01-20 | S | D | 8,343 | $60.52 | 7,907 | D | — | — | (F9) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.00 to $60.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2022-01-19 | S | D | 555 | $62.24 | 6,250 | D | — | — | (F8) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $62.15 to $62.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2022-01-20 | M | A | 10,000 | $18.00 | 16,250 | D | — | — | |
| 5 | Common | Common Stock | 2022-01-19 | S | D | 1,556 | $61.51 | 6,805 | D | — | — | (F7) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.09 to $61.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2022-01-19 | S | D | 7,889 | $60.55 | 8,361 | D | — | — | (F6) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.07 to $61.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2022-01-19 | M | A | 10,000 | $18.00 | 16,250 | D | — | — | |
| 8 | Common | Common Stock | 2022-01-18 | S | D | 1,300 | $64.66 | 6,250 | D | — | — | (F5) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.23 to $65.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 9 | Common | Common Stock | 2022-01-18 | M | A | 10,000 | $18.00 | 16,250 | D | — | — | |
| 10 | Common | Common Stock | 2022-01-18 | S | D | 3,409 | $61.70 | 12,841 | D | — | — | (F2) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.97 to $61.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 11 | Common | Common Stock | 2022-01-18 | S | D | 3,294 | $62.34 | 9,547 | D | — | — | (F3) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.98 to $62.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 12 | Common | Common Stock | 2022-01-18 | S | D | 1,997 | $63.48 | 7,550 | D | — | — | (F4) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $63.18 to $64.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 13 | Derivative | Stock Option | 2022-01-18 | M | D | 10,000 | $0.00 | 144,949 | D | $18.00 · — to 2030-03-25 | 10,000 Common Stock | (F11) The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024. |
| 14 | Derivative | Stock Option | 2022-01-20 | M | D | 10,000 | $0.00 | 124,949 | D | $18.00 · — to 2030-03-25 | 10,000 Common Stock | (F11) The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024. |
| 15 | Derivative | Stock Option | 2022-01-19 | M | D | 10,000 | $0.00 | 134,949 | D | $18.00 · — to 2030-03-25 | 10,000 Common Stock | (F11) The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024. |